Skip to main content

Table 4 Cost-effectiveness analysis results with 40% reduction in single exit price applied (USD, 2020–2021 prices)

From: A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Strategy

Cost (USD)

QALY

ICER (USD/QALY gained)

NPH once daily

32.27

0.8321

 

Detemir once daily

77.28

0.8343

Ext. dominated

Glargine U300

94.00

0.8351

20,898.47

Glargine U100

114.71

0.8344

Abs. dominated

Degludec

145.84

0.8365

38,172.30

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us